ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Ataraxis AI
Ataraxis is seeking a high-ownership full-stack builder to develop and deploy AI-native precision medicine tools for oncology. This role spans frontend web portals, backend order services, and machine learning infrastructure running on Google Cloud and Modal. Candidates will create physician-facing applications using modern frameworks while managing complex integrations and regulated reporting requirements.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2023
Ataraxis AI is a pioneering company focused on transforming cancer care through the application of AI precision medicine. Their flagship product, Ataraxis Breast, is the first clinically available AI-native platform specifically designed for breast cancer, utilizing advanced multi-modal tools to enhance treatment selection and improve patient outcomes. The company's technology harnesses cutting-edge artificial intelligence methods to analyze diverse patient data, enabling the identification of novel clinical features that can guide personalized treatment strategies. Ataraxis AI collaborates with leading international cancer centers to refine and implement their groundbreaking solutions in clinical settings.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ataraxis AI.
Right around the average for this role